David J. Andorsky, MD, board-certified medical oncologist and hematologist at Rocky Mountain Cancer Centers, discussed findings from a study on patterns of Bruton tyrosine kinase (BTK) inhibitor care use and social determinants of health (SDOH) among patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
David J. Andorsky, MD, board-certified medical oncologist and hematologist at Rocky Mountain Cancer Centers, a practice in the US Oncology Network, discussed findings from a study on patterns of care and social determinants of health (SDOH) among patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The research was presented at the 2023 American Society of Hematology Annual Meeting.
Transcript
Your study found that rural settings were associated with different treatment patterns for CLL/SLL. Can you briefly discuss those trends and their implications?
What we observed was that the patients in a rural environment were actually a little more likely to receive one of the newer medications, either acalabrutinib or zanubritunib. It was not a huge effect size, and the number of patients in a rural environment were small in the study, so I would take those findings with sort of a note of caution or that it's more hypothesis-generating as opposed to definitive. It was reassuring, though, because I think one might have expected that you would see patients not getting those new medications in what's traditionally thought of as a kind of medically underserved environment. It's nice to see that those patients, in our network at least, have access to the latest medications.
As novel therapies are tested in clinical trials and approved, what can be done to try and close treatment gaps fueled by SDOH?
Understanding what patients' barriers are to receiving treatment. Is it a financial barrier? Is it that they don't have a ride to get to their office visits? That can be a big burden for people—I think less so with the oral medications because you don't have to come to clinic every week, but that still can be a barrier. Also, just medical literacy, patients not understanding why they need to take a treatment [or whether it is] really necessary. Those are all things that I think we can all keep working to address.
This transcript has been lightly edited for clarity.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More